Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?

Regeneron Pharmaceuticals stock has underperformed this year, down around 1%, but the company demonstrated strong fundamentals in its last earnings report with 17% revenue growth and impressive drug sales. With a modest valuation (19x trailing earnings vs. S&P 500's 23x), a robust pipeline of 50 product candidates, and upcoming Q3 earnings on Oct. 30, analysts suggest the stock could be poised for a rally and represents a solid value buy for long-term investors.